EGFR and non-small cell lung carcinoma: The test allows the detection of epidermal growth factor receptor (EGFR) mutations using cfDNA from plasma samples in non-small cell lung cancer (NSCLC) patients for guiding the selection of patients who could benefit from anti-EGFR therapies [35].